Investors should monitor upcoming clinical readouts, particularly the GFORCE-1 data for MRT-8102 in H2 2026 and the initiation of multiple Phase 2 trials. The extended cash runway reduces near-term dilution risk and supports value inflection through multiple catalysts.
Price Chart
Executive Summary
Monte Rosa Therapeutics reported Q4 and full-year 2025 financial results alongside significant clinical progress, including positive Phase 1 data for MRT-8102 showing 85% CRP reduction in high-CVD-risk patients and a 100% PSA response rate for MRT-2359 in mCRPC patients with AR mutations. The company raised $345 million in gross proceeds from a follow-on offering, extending its cash runway into 2029 to fund multiple upcoming Phase 2 trials.
Key Financial Metrics
Key Facts
- MRT-8102 demonstrated 85% reduction in CRP levels after four weeks in elevated CVD-risk subjects, with 94% achieving CRP <2 mg/L
- Unblinded safety data from 88 participants showed no serious adverse events and a favorable tolerability profile for MRT-8102
- MRT-2359 in combination with enzalutamide achieved 100% PSA response rate in mCRPC patients with AR mutations (5 of 5 patients), including partial responses
- Company raised $345 million in gross proceeds from a January 2026 follow-on offering, with net proceeds ~$323.8 million
- Cash position post-offering supports operations into 2029, enabling multiple Phase 2 initiations
- Novartis to initiate multiple Phase 2 studies of MRT-6160 in immune-mediated diseases, with Monte Rosa eligible for up to $2.1B in milestones and 30% U.S. profit share
- Planned Phase 2 studies for MRT-8102 in CVD, gout, and hidradenitis suppurativa to initiate between H2 2026 and H1 2027
Financial Impact
Cash position increased by $345M gross from equity offering; collaboration revenue declined YoY from $75.6M to $123.7M but driven by milestone timing, while R&D spend increased to $141.5M
Risk Factors
- Clinical development risk in upcoming Phase 2 trials despite strong Phase 1 signals
- Heavy reliance on partnership execution with Novartis and Johnson & Johnson
- No product revenue yet; long path to commercialization
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3256993 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 1, 2026 26d ago | 8-K | $11.26 | awaiting T+60 | — | $10.61 (−5.77%) |
Sep 30, 2026 26d ago | Press Release | $11.26 | awaiting T+60 | — | $10.61 (−5.77%) |
Aug 6, 2026 11w ago | 8-K | $15.71 | awaiting T+60 | — | $10.61 (−32.46%) |
Jul 17, 2026 14w ago | Insider Cluster | $23.48 $9.89 | ▼ −57.88% | ▼ −62.72% | $10.61 (−54.81%) |
Jul 7, 2026 15w ago | Insider Cluster | $24.06 $11.93 | ▼ −50.42% | ▼ −52.73% | $10.61 (−55.90%) |
Jul 1, 2026 16w ago | Insider Cluster | $24.21 $11.72 | ▼ −51.59% | ▼ −54.60% | $10.61 (−56.18%) |
Jul 1, 2026 16w ago | Insider Cluster | $24.21 $11.72 | ▼ −51.59% | ▼ −54.60% | $10.61 (−56.18%) |
Jun 29, 2026 17w ago | 144 | $24.20 $11.89 | ▼ −50.87% | ▼ −54.43% | $10.61 (−56.16%) |
Jun 25, 2026 17w ago | Insider Cluster | $22.29 $12.60 | ▼ −43.47% | ▼ −49.56% | $10.61 (−52.40%) |
Jun 2, 2026 20w ago | Insider Cluster | $17.59 $14.32 | ▼ −18.59% | ▼ −21.09% | $10.61 (−39.68%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers